Focus:
News
-
22 November 2019
ViiV to develop bNAb candidate to treat and prevent HIV
ViiV Healthcare has agreed to develop an investigational broadly neutralising antibody (bNAb) N6LS to treat and prevent human immunodeficiency virus 1 (HIV-1) infection.
-
22 November 2019
AstraZeneca’s Calquence gets FDA approval under Project Orbis
AstraZeneca has secured approval from the US Food and Drug Administration (FDA) for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in adults.
-
22 November 2019
AbbVie signs licensing deal with Harpoon Therapeutics
AbbVie has entered an option and licence partnership with Harpoon Therapeutics for exclusive, global rights to a multiple myeloma asset HPN217.
-
21 November 2019
Bristol-Myers closes $74bn Celgene acquisition
Bristol-Myers Squibb (BMS) has closed the acquisition of Celgene via a cash and stock transaction worth an equity value of $74bn, or $102.43 per share.
-
21 November 2019
AbbVie leverages Dragonfly’s NK cell immunotherapy technology
US-based Dragonfly Therapeutics has announced it has signed a multi-target collaboration with AbbVie to advance immunotherapies created using its Tri-specific Natural Killer (NK) cell engager Therapies (TriNKET) technology for autoimmune...
-
21 November 2019
Alnylam’s Givlaari secures FDA approval for acute hepatic porphyria
Alnylam Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for subcutaneous injection of its Givlaari (givosiran) drug to treat acute hepatic porphyria (AHP) in adults.
-
21 November 2019
Lilly to invest $400m to boost manufacturing capacity in US
Eli Lilly is set to invest $400m to boost the capacity of its manufacturing facilities at its technology centre campus in Indianapolis, Indiana, US.
-
20 November 2019
Two patients respond well to Vertex and CRISPR’s gene-editing therapy
Vertex Pharmaceuticals and CRISPR Therapeutics have announced promising safety and efficacy results from two patients treated in two Phase I/II trials of its investigational CRISPR/Cas9 gene-editing therapy CTX001.
-
20 November 2019
EC approves Janssen’s Darzalex multiple myeloma combination
Janssen Pharmaceutical has received approval from the European Commission (EC) to market Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (DRd) for multiple myeloma.
-
20 November 2019
Idorsia and Antares partner on auto-injector for AMI drug selatogrel
Idorsia Pharmaceuticals has signed a global agreement with Antares Pharma to develop a self-administrable, auto-injector product for its acute myocardial infarction (AMI) drug, selatogrel.
Close
Close
Close
Go Top
